title: [Effect of therapeutic drug monitoring of amitriptyline and genotyping on efficacy and safety of depression therapy].
abstract: Modern pharmacotherapy is based on precise adjustment of a dosage schedule to individual requirements of patient. Therapeutic drug monitoring is a method that allows for a more effective treatment approach, especially in the case of a narrow therapeutic index of a drug. Tricyclic antidepressant drugs are characterised by narrow therapeutic index as well as relationship between serum drug concentration and side effects. It was demonstrated that interindividual variability of blood concentrations of tricyclic antidepressant drugs is related to genetic polymorphism of oxidating enzymes participating in metabolism of these drugs. The aim of the study was to estimate the impact of therapeutic drug monitoring of tricyclic antidepressant drugs as well as genotyping on efficacy and safety of endogenous depression therapy. The study included 9 patients with established diagnosis of endogenous depression. Blood serum concentrations of amitryptyline was measured by fluorescence polarisation immune assay (FPIA, Abbott system). Genotype of cytochrome P450 isoenzyme CYP2D6 was determined using PCR-RFLP method. It was demonstrated that monitoring therapy of tricyclic antidepressant drugs in combination with determination of the genotype seems to be more safe and effective. Monitoring therapy and genotyping may be less expensive than the costs of prolonged hospitalisation and risk of side effects.
authors.forename: A
authors.initials: A
authors.lastname: Ostapowicz
authors.forename: M
authors.initials: M
authors.lastname: Zejmo
authors.forename: J
authors.initials: J
authors.lastname: Wrześniewska
authors.forename: M
authors.initials: M
authors.lastname: Białecka
authors.forename: W
authors.initials: W
authors.lastname: Górnik
authors.forename: B
authors.initials: B
authors.lastname: Gawrońska-Szklarz
mesh_terms: D000328:Adult; D000639:Amitriptyline / Q000097:blood* / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000097:blood* / Q000627:therapeutic use*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003866:Depressive Disorder / Q000188:drug therapy*; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D000639:Amitriptyline; D019389:Cytochrome P-450 CYP2D6